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Abstract 
Background 
Intensive self-monitoring of blood glucose levels in patients with diabetes achieves optimal glucose 
control, hence reducing the likelihood of complications. 
Methods 
This is a prospective, cross sectional study targeting adults with diabetes in community pharmacies 
and diabetes patient groups in Central and West London, over a period of 10 weeks. 
Results and Discussion 
In all, 207 adults with diabetes were included in the analysis of results.  This study showed that 
24.2% (n=50/207) of the participants were asked to monitor their blood glucose between 3-4 times 
per day when diagnosed, however only 14.0% (n=29/207) were compliant when the study 
commenced. A further decline in adherence, from diagnosis to study initiation, was seen in 
participants who had been asked to monitor their blood glucose levels at least five times per day. 
When questioned about their reasons for poor adherence, 59.2% (n= 123/207) of the cohort 
indicated that this is due to the painful, uncomfortable and inconvenience nature of testing. In 
addition, 75.8% (n=157/207) of the participants expressed their desire for a non-invasive monitoring 
device and 73% (n=151/207) would be satisfied using one of the pre-selected advanced technologies 
to monitor their blood glucose levels. The favoured advanced technology, selected by 49.8% 
(n=103/207) of participants, was the wristband. Statistical significance was seen between the type of 
diabetes and the device selected, with type 1 diabetes patients preferring contact lenses (p=0.0219) 
and tattoos (p<0.0001), whereas type 2 diabetes  patients preferred earlobe sensors (p=0.0009) and 
saliva analysers (p<0.0001) .Participant gender, age and ethnicity also influenced device selection. 
 
Keywords: Complications, diabetes mellitus, monitoring, technology 
 
 
 
 
1. Background 
Diabetes mellitus is described by the World Health Organisation (WHO) as a global epidemic, with 
422 million adults currently living with this chronic condition. [1]It is anticipated that this number will 
rise steeply to 552 million adults by 2030.[1]  In the United Kingdom, diabetes mellitus costs the 
National Health Service (NHS) £10 billion per annum, with 80% of this figure allocated to treating 
complications associated with the condition.[2]  
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Individuals with diabetes can experience acute and chronic complications as a result of the 
condition. Acute complications of diabetes include episodes of hyperglycaemia and hypoglycaemia, 
where the blood glucose levels rise above 10 mmol/L or decrease below 4 mmol/L respectively. [3] 
Chronic complications experienced by diabetes patients range from heart attacks and strokes to 
retinopathy, renal failure, neuropathy and lower limb amputations. [4] To minimise the likelihood of 
diabetes complications, patients are encouraged to self-monitor their blood glucose levels in order 
to achieve optimum control [5]. This advice has been supported by the findings from many studies 
which have explored the relationship between blood glucose control and the incidence of diabetes 
complications. Research conducted by Martin S, Schneider B et al [6] investigated whether there was 
a relationship between self-monitoring of blood glucose (SMBG) and disease related morbidity and 
mortality, concluding that SMBG was associated with a reduction in diabetes complications.  In 
addition, the results from a 20-year, multi-centre study, conducted by Holman R and Turner R [7], 
showed that complications associated with type two diabetes (T2DM), could be significantly reduced 
by improving blood glucose control.  
Type 1 diabetes (T1DM) results from the autoimmune destruction of insulin-producing pancreatic 
beta cells. [8] Whereas T2DM occurs due to an alteration in the balance between insulin sensitivity 
and insulin secretion. [9] At present the National Institute of Clinical Excellence (NICE) recommends 
that T1DM patients should monitor their blood glucose levels at least four times per day and should 
aim for a glycosylated haemoglobin (HbA1c) value of less than 48mmol/mol (6.5%) [10].  For T2DM 
patients, NICE specifies a HbA1c target between 48mmol/mol (6.5%) and 53mmol/mol (7.0%), 
although recent monitoring guidelines have changed [10]. The target for T2DM varies depending on 
the type of diabetes management plan and whether the patient takes antihyperglycaemic agents, 
which may potentiate hypoglycaemia. Research by Mindera et al [11] revealed that when T1DM 
participants (n=150) increased the number of SMBG tests per day, it resulted in a HbA1c value 
reduction. Their research showed that participants who practiced SMBG ≤4 per day, reported a 
reduction of -0.19% in HbA1c with each additional SMBG performed (p<0.001). Similarly, a study 
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conducted by Zieglar et al [12] revealed that patients who monitored ≤5 times a day experienced a -
0.2% decrease in HbA1c (p<0.001), with each additional measurement of SMBG performed. Despite 
these findings, recommendations and the emphasis put on self-monitoring by UK healthcare 
professionals, research by Wagner J, Malchoff C et al [13] has shown that the level of non-adherence 
amongst patients with diabetes remains high, concluding that less-invasive SMBG technologies could 
enhance monitoring adherence.    
Over the past four decades there has been a transition from measuring glucose concentrations using 
urine samples, to the development of SMBG meters [14] and reagent strip systems [14]. More than 
60 glucose monitoring devices/strips are available in the UK with only few offered on the NHS. As 
the meters have evolved, they have become smaller, more varied in design and more advanced in 
their data management and connectivity functions. [14] To address some of the issues associated 
with SMBG adherence, several advanced technologies are currently undergoing development. For 
this research, six advanced SMBG technologies were selected, including contact lens sensors which 
measure ocular glucose concentrations [15], smart tattoos which change colour accordingly [16] and 
wristbands which function via reverse iontophoresis [17]. In addition to the aforementioned 
technology, saliva glucose analysers [18], skin sensors [19] and earlobe sensors, which detect 
glucose concentrations via ultrasound [20], were also chosen.  
This study aimed to investigate patients’ with diabetes perceptions towards current and advanced 
blood glucose monitoring technologies, in addition to exploring diabetes patients’ expectations in 
relation to future SMBG devices.  
 
2. Methods 
A prospective, cross sectional, descriptive study was undertaken, in Central and West London, UK. 
These areas were selected because London has an ethnically diverse population, with 475,000 
people currently living with diabetes. [21] A questionnaire was designated as the data collection tool 
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for this study. It was designed to investigate participants’ perceptions towards current and advanced 
blood glucose monitoring devices, in addition to investigating factors that influence device 
acceptability. The questionnaires were anonymously distributed in community pharmacies and 
diabetes patient groups in Central and West London. Each participant was supplied with a copy of 
the questionnaire, a participant information sheet and an additional printed sheet, containing 
information regarding six, pre- selected advanced technology devices. The participants returned the 
questionnaire upon completion; however, they were able to retain the information sheets for future 
reference.  
The questionnaire was composed of a mixture of open ended and closed ended questions, 
producing a total of 27 questions, which were separated into following six sub-sections: health 
perceptions (including several questions about diabetes complications), healthcare professionals, 
monitoring -past, monitoring-present, new technologies and demographics. Our questions about 
monitoring frequency were adapted from questions previously used by Barnard, K.D. et al [27].  One 
of the questions in the healthcare professional section utilised a five-point Likert scale to assess 
participant perceptions and attitudes towards their health care professional. Similarly, there was 
another question which utilised a five-point Likert scale in the new technologies section. In the 
latter, participants were asked to rate a number of potential design features for future blood glucose 
monitoring technology. There were also two questions within the monitoring-present section, which 
utilised a 10-point Likert scale to ask participants to describe how happy they were with their 
current blood glucose levels and current monitoring methods. By using Likert scale questions, 
participants were able to select the most appropriate option which aligned with their opinions . An 
open-ended question was used to ask the patients if they would use the new monitoring devices if 
available in the market and why they feel the new technology would be better than the current 
methods available. Also, participants were asked to identify any additional features they would like 
to see in a glucose monitoring device. Participants were not asked to provide any identifiable 
information. 
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Prior to commencing this research, a pilot study was conducted involving fourteen participants with 
diabetes. This sample size equated to 5% of our required sample size for the main study, and it had a 
ratio reflective of type 1 and type 2 diabetes. Participants were selected at random to participate in 
the pilot study, and their input was used for face and content validation of the questionnaire.  
Findings from the pilot study suggested that the survey structure was highly welcomed, and no 
adjustments were necessary. To minimise study bias, individuals who participated in the pilot study 
were excluded from main study.  
To determine the sample size required for this study, a power calculation was carried out. Based on 
diabetes mellitus prevalence of 475,000 across London, the minimum sample size at 90% confidence 
level and 5% margin of error was 271. With a prevalence of 10% T1DM and 90% for T2DM in UK, at 
least 27 patients with T1DM should be recruited.[22]. For T2DM at least 244 patients should to be 
recruited to achieve CI of 90%. 
The inclusion criteria required participants to have diabetes, have monitored their glucose level 
previously , aged over 18 years and able to speak and understand English in order to provide 
consent. Participants were excluded if they were aged below 18 years old, did not monitor their 
blood glucose, were unable to understand written or spoken English, had cognitive impairment, or 
were unwilling to participate.   Participants were supplied with an information sheet which clearly 
explained that their consent would be implied if they were to complete the approved questionnaire; 
however, participants were informed that they could withdraw from the study at any point. In 
addition, patients were provided with monitoring device information sheet written in lay terms and 
described how to use the device and how the device works- in terms of monitoring glucose- and 
whether it was continuous or non-continuous glucose monitoring device. Participants were advised 
to speak to the pharmacist or the researcher or to contact the research team if they have any 
further queries. 
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The study was conducted over a ten-week period from January 2015 – March 2015. The completed 
questionnaires were collected immediately, if the researcher was present or left at the community 
pharmacies to be collected at the end of the data collection period. All collected questionnaires 
were checked for meeting the inclusion criteria before analysis. The collected data was tabulated 
and analysed using Microsoft Excel. A chi-square inferential test was used to identify correlations 
between demographics and responses provided. The level of statistical significance was set at 
p<0.05. The questionnaire was approved by the Faculty of Science, Engineering and Computing 
Ethics Committee at Kingston University. 
Results 
A total of 377 questionnaires were distributed and 211 were returned. However, 16 were excluded 
as 4 participants did not have diabetes and 12 never monitored their glucose level therefore did not 
fit the inclusion criteria. Consequently, a 51.7% (195/377) response rate was achieved. Demographic 
details of the cohort are presented in Table 1. Although the sample size is under-representative for 
T2DM, it is over-representative  for T1DM as 76 patients with T1DM were recruited. 
Incidence of Diabetes Complications 
This study identified that 42.1% (n=82/195) of the cohort had experienced diabetes complications. 
The following conditions: retinopathy, nephropathy, neuropathy, cardiovascular conditions and limb 
amputations, were defined in the questionnaire as complications. In addition, the results showed 
that 28.2% (n=55/195) of the cohort who had suffered from complications, had lived with diabetes 
for over 10 years (Figure 1). These findings demonstrate a positive correlation between time elapsed 
since diagnosis and the incidence of complications (r=0.9). 
  Participants were asked about their blood glucose control and their experiences of hyperglycaemic 
episodes (blood glucose level of 10 mmol/L or above) to determine whether complications were 
associated with poor control. Irrespective of diabetes type, all participants reported an HbA1c value 
Page 8 of 21
9 
 
higher than that recommended by NICE. The results showed that 87.6% (n= 171/195) of the cohort 
had experienced hyperglycaemic episodes. In addition, the results also showed that increased 
frequencies of hyperglycaemic events were associated with poor diabetes control (r=0.9).  
Frequency of blood glucose monitoring 
The cohort was asked about how often they been asked to monitor their blood glucose levels and 
this data was compared to their current monitoring frequency enabling participant adherence to be 
assessed. The data shows that 43.4% (n=33/76) of participants with type 1 diabetes were asked by 
their healthcare team to monitor their blood glucose between three or four times a day. However, a 
tenth of those did not follow this recommendation as only 34.2% of the participants indicated 
following their recommended monitoring regimen. On the other hand, 42.9% (n=51/119) of 
participants with type 2 diabetes were asked to monitor their glucose between 3-4 times per day, 
however only 2.5% (n=3/119) were following this monitoring guidance. For type 2 participants, 
increasing the recommended number of glucose monitoring times per day was associated with a 
significant decline in adherence.  
Current technology usage and perceptions 
When the participants were asked about their current methods of monitoring glucose levels, 77.8% 
(n=158/195) reported using a finger prick test, whilst 6.6% (n=13/195) measured glucose levels using 
urine samples and 2.0% (n=4/195) used a continuous blood glucose monitor (CGM) (Figure 2a). 
 
Using a Likert scale (0-10), participants were asked to ascribe a quantitative value to their level of 
satisfaction with their current blood glucose monitoring equipment. A value of 0 was given by 
participants who were unhappy with their current equipment whilst a value of 10 would be given by 
a participant who was very happy with their current equipment. Overall, 60.0% (n=117/195) 
participants rated their satisfaction level as ≤5, showing a significant number of the cohort being 
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dissatisfied with the technology used. Reasons given for the rating provided were the monitoring 
device being  uncomfortable [33.8% (n=66/195)], inconvenient [36.9% (n=72/195)] and painful 
[29.2% (n=57/195)]  
(Figure 2b). 
 
Desired features of future blood glucose monitoring technology  
The cohort was asked to rate a number of potential design features for future blood glucose 
monitoring technology using a Likert scale with 1 being (lowest) to 5 (highest) rating, depending 
upon the perceived level of importance.  The preferred choice, reported by 49.2% (n=96/195) of the 
participants, was the ‘easy to use’ design feature, also 49.2% (n=96/195) required the technology to 
be painless, thus improving the overall comfort level.   The cohort ascribed low values to several 
design features including style (41.0%) and voice control (33.8%), suggesting that these features 
were perceived as less important when considering the future design of blood glucose monitoring 
technologies. More than three quarters (75.3%) of the participants provided details of their desire 
for non-invasive monitoring technologies. In addition, over half the participants (52.8%) preferred 
non-continuous glucose monitoring in comparison to CGM. The results showed a statistical 
significance (p<0.0001) between type of monitoring preference and the daily frequency of diabetes 
testing, hence those who tested more frequently preferred CGM. 
Perceptions towards advanced blood glucose monitoring technology 
Participants were shown six potential blood glucose monitoring devices with 74.3% (n=145/195) of 
the cohort saying they would be happy using the new devices, which may be released in the near 
future. Overall 49.7% (n=97/195) of participants preferred the wristband option (Figure 3a). There 
was no statistical significance (p>0.05) between the selection of wristbands and type of diabetes. 
However, there was statistical significance between type of diabetes and other device preferences. 
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T1DM participants preferred contact lenses (p<0.05) and tattoos (p<0.0001), whereas T2DM 
participants showed statistical significance preference towards earlobe sensors (p<0.0001) and saliva 
analysers (p<0.0001).  
The study considered whether gender had an impact on device selection (Figure 3b). Males showed 
a statistical significance preference for the wristband (p<0.05). However, females showed a 
statistical significance preference towards contact lenses (p<0.01) and tattoos (p<0.001). 
Additionally, the influence of age on device selection was also investigated. Results in Figure 3c show 
that tattoos were the preferred device choice for 47.2% (n=17/36) of participants, aged under 30 
years old. However, tattoos were not selected by any participant aged over 30 years old. Participants 
preference towards saliva analysers varied across the age groups, with 53.7% (n=29/54) participants, 
aged between 50-59 years, selecting this device as their first choice whereas saliva analysers were 
not selected by any participant aged between 21-29 years old. When considering participants, who 
were 60 years of age or older, 73.8% (n= 65/88), preferred the wristband option (Figure 3c).  
A difference between device selection and participant ethnicity was also observed (Figure 3d). All 
ethnic groups selected earlobe sensors; however this device was particularly popular amongst black 
participants. Interestingly smart tattoos, saliva analysers and skin sensors were selected by all 
ethnicities except black participants.  
Discussion 
It is widely recognised that elevated blood glucose levels, poor monitoring adherence and extensive 
disease duration are all contributory factors to the development of diabetes complications. This 
study has identified that all participants, irrespective of their diabetes type, failed to achieve a 
HbA1c value within the target range, as specified by NICE, with 42.1% of participants experiencing 
complications. 
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In this study participants were asked about how frequently they had been recommended to monitor 
their blood glucose levels, compared to their actual monitoring frequency. This enabled participant 
adherence to be assessed. There was a noticeable decline in participant adherence from what had 
been recommended by their healthcare team. Non-adherence to monitoring can lead to disease 
related to complications.  The research conducted by Martin S, Schneider B et al, [6] investigated the 
incidence of disease related complications and mortality in diabetes sufferers. Their findings showed 
that the incidence of complications was lower in the group who regularly monitored their blood 
glucose in comparison to the group who failed to monitor. Rodrigeuz-Gutierrez [28] acknowledged 
the wealth of evidence surrounding blood glucose monitoring in diabetes; however, they also report 
discordance in the literature surrounding frequent monitoring and the reduction of diabetic 
complications. Further research into the association between frequent monitoring and diabetic 
complications is required.  
This study aimed to investigate patients’ with diabetes perceptions towards current and advanced 
blood glucose monitoring technologies. When participants were questioned about their reasons for 
their poor adherence, it was interesting to discover that most of the cohort was relatively 
dissatisfied with their current monitoring technology, citing their reasons for dissatisfaction as 
painful, inconvenient and uncomfortable testing. These findings have been supported by qualitative 
research conducted by Wong O, Siew C et al [23] which recognised that the uptake of self-
monitoring is low in many countries and reported that the factors influencing this uptake include the 
painful nature, inconvenience and complexity of currently available self-monitoring blood glucose 
(SMBG) equipment.  
Self-monitoring is an integral part of diabetes management, aimed at achieving optimum blood 
glucose control however a review by Benjamin EM [24], recognised that the true potential of blood 
glucose monitoring has not yet been reached, thus providing support for new, innovative 
technologies to improve monitoring adherence. This study differentiates itself from previous 
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research by asking participants about their attitudes and perceptions towards advanced 
technologies while considering the factors that may influence their choice when selecting a 
monitoring device. When questioned, almost three-quarters of the cohort were prepared to try a 
less invasive, advanced technology to monitor their blood glucose levels. These findings are 
supported by research conducted by Wagner et al [13] which showed that over two-thirds of their 
study participants reported avoiding blood glucose monitoring, due to the invasive nature of testing. 
It was also reported that invasive technology was associated with increased levels of anxiety and 
suggested that this was another serious barrier to self-monitoring of blood glucose levels [13]. The 
psychological impact of SMBG is beyond the scope of this study; however, the number of non-
compliant participants was similar in both studies. 
Participants were asked about desired design features for advanced technology devices. They cited 
an easy to use, pain free and comfortable product was most important to them, whereas design 
features such as style and voice control were considered less important. Furthermore, this study 
aimed to investigate whether patient factors influenced advanced technology device acceptability. 
Prior to commencing this study, six advanced technologies, which have been proposed for future 
development, were selected. Over three-quarters of the participants were prepared to try an 
advanced technology monitoring device. The preferred device, selected by 49.7% of participants was 
the wristband. There was no statistical significance between the selection of wristbands and type of 
diabetes. However, there was statistical significance between the type of diabetes and other device 
preferences. T1DM participants preferred contact lenses and smart tattoos, whereas T2DM 
participants preferred earlobe sensors and saliva analysers. Looking closely at T1DM participants 
who opted for tattoos, it was found that all the participants were under the age of 29 years old with 
82.3% of those being females (n=14/17). 
The results from this study also show that gender can influence advanced technology device 
acceptability. Statistical significance was detected between males and their preference for the 
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wristbands, whereas females showed a statistical significance in their preference towards contact 
lenses and smart tattoos. The results come in line with the previous findings by Kelvin et al [24] who 
surveyed 1850 persons aged between 12-55 years old. It was concluded that young, highly educated 
females tend to wear contact lenses more often for cosmetic reasons.  Tattoos are perceived by 
females as a body art, nonetheless previous studies did not report any significance difference 
between gender and prevalence of tattoos [26, 27]. 
Furthermore, the influence of age and ethnicity of device acceptability was also investigated. The 
results showed that participants under 30 years old preferred smart tattoos, whereas participants 
who were 60 years or older preferred wristbands. Participant preference towards the other devices 
varied across the age ranges, with saliva analysers being the most popular type of monitoring device 
in participants aged between 50 and 59 years. When considering the influence on ethnicity on 
device selection, earlobe sensors were the most popular choice amongst black participants, whereas 
smart tattoos, saliva analysers and skin sensors were selected by all ethnicities apart from black 
participants. aThus this study shows that diabetes patients are open to try new monitoring devices 
and patients’ demographics will affect their selection of future glucose monitoring devices.  
This study has some limitations. Firstly, the sample size for this study was relatively small and 
participants were selected from an urban community in Greater London, which may limit the 
generalisability of our results. Also, participants choice of monitoring device may have been 
influenced by confounding factors; however, we were not able to account for confounding factors in 
our statistical analysis. Further work with a larger sample size is required to enable a clear conclusion 
of variable influencing the monitoring device preference. 
Conclusion 
This research, despite the small sample size, has provided a remarkable insight into patient 
perceptions towards advanced technologies for blood glucose monitoring. The results showed that a 
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significant proportion of participants would be willing to try an advanced technology to monitor 
their blood glucose levels. Additionally, this research has also identified that patient factors such as 
type of diabetes, gender, age and ethnicity may be influential in device selection. For instance T1DM 
participants preferred contact lenses and tattoos, whilst T2DM participants opted for earlobe 
sensors and saliva analysers. The results from this study could be used to inform future monitoring 
device design and manufacturing.   
These initial findings call for further research to be conducted, in order to identify other patient 
factors which may influence advanced technology device acceptability. This research considered six 
different advanced technology devices, thus further work should consider alternative monitoring 
devices. 
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Figure 1: The number of diabetes complications and average duration of diagnosis in study 
population (n=195). 
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Figure 2: Current methods used to monitor glucose by participants (a) and their perceptions 
of the selected glucose-monitoring techniques (b) (n=195). 
 
 
Figure 3: Patients’ preferred choice of advanced glucose monitoring technologies (a) and patients’ 
choice of the selected monitoring devices by gender (b), age group (c) and ethnicity (d) (n=195) 
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Table 1: Demographics of eligible study participants 
 
 
Parameter Type 1 diabetes  Type 2 diabetes  
Diabetes type % 38.9 (n=76) 61.1 (n=119) 
Modal Age Range >60 years >60 years 
Gender (male/female) % 56.6 (n= 43) / 
43.4 (n=33) 
63.8 (n=76) /  
36.1 (n=43) 
Ethnicity 
(White/Black/Asian/Other/ Prefer 
not to say) % 
35.5 /5.3/47.4/7.9/3.9 26.9/5.0/41.2/25.2/1.7 
Page 21 of 21
